The 17th JFCR－ISCC
December 5 (Wed)- 6 (Thu), 2012
Miraikan (National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan
The 17th JFCR-International Symposium on Cancer Chemotherapy (JFCR-ISCC) is scheduled as indicated above. I sincerely welcome your participation in this Symposium.
The JFCR-ISCC aims at information exchange on the latest findings of newly developing molecular-targeted anti-cancer drugs and the related topics. Molecular-targeted anti-cancer drugs have been developing prominently with global standards. Meanwhile, already launched molecular-targeted drugs have often been faced with rather quickly acquired resistance, and various challenges against the resistance are rapidly evolving. Accessing to these information is indispensable, moreover, informal exchanges of personal, very specific, or even unsuccessful experiences, are critically valuable for effective achievements of drug development. I believe the JFCR-ISCC with relatively small size will provide you an excellent opportunity for such communication through personal contacts.
In the upcoming 17th JFCR-ISCC, mechanisms of drug resistance and their conquest are the main topics. I hope the Symposium would be an excellent occasion for you to access the domestic and international developments of new anticancer drugs and also to meet scientists, clinicians, and drug developers.
Looking forward to seeing you in Tokyo,
Mitsuaki Yoshida, Ph.D. Chairman, JFCR-ISCC Director, Cancer Chemotherapy Center, JFCR |
(*Program update)
| To attend the Luncheon Seminars, please receive Luncheon Seminar Ticket at “Luncheon Ticket Desk” . The desk will open from 11:00 on December 5. |
The 17th Symposium Program Committee
Naoya Fujita (Program Committee Chairman, Cancer Chemotherpy Ctr.)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd.)
Kiyohiko Hatake (Cancer Chemotherpy Ctr.)
Manabu Kawada (Inst. Microbial Chem.)
Kei Muro (Aichi Cancer Ctr. Hospital)
Atsushi Ohtsu (National Cancer Ctr. Hospital East)
Isamu Okamoto (Kinki Univ.)
Hiroyuki Seimiya (Cancer Chemotherpy Ctr.)
Toshimitsu Uenaka (Eisai Co., Ltd)
Kazuhito Yamamoto (Aichi Cancer Ctr. Hospital)
Seiji Yano (Kanazawa Univ.)
December 5
11:00-13:00
Poster mounting
12:00
Committee Meeting
Opening remark
13:00-13:10
Mitsuaki Yoshida (Cancer Chemotherapy Center)
Opening remark
IPatient Selection Strategies in Early Clinical Studies
Chairpersons: Anthony W. Tolcher and Atsushi Ohtsu
13:10-13:40
Jaap Verweij (Erasmus University Medical Center)
The future of early clinical trials in new drug development
13:40-14:00
Toshio Shimizu (Kinki University)
Personalizing cancer treatment of targeting of PI3K/AKT/mTOR pathway in patients with advanced cancer
14:00-14:10
Discussion
14:10-14:30
Coffee break
II Companion Diagnostics
Chairpersons: Gregory K. Pennock and Yoshikazu Sugimoto
14:30-15:00
Mark J. Ratain (The University of Chicago)
Companion diagnostics: Consideration of tumor heterogeneity
15:00-15:20
Kengo Takeuchi (Cancer Institute, JFCR)
Discovery of novel fusion genes by histomolecular pathology
15:20-15:30
Discussion
Poster Session
15:30-16:30
P1
Naoki Kaneko (Astellas Pharma Inc.)
Sepantronium bromide (YM155), a survivin suppressant, enhances the antitumor effect of rituximab in diffuse large B cell lymphoma (DLBCL).
P2
Osamu Tohyama (Eisai Co. Ltd.)
Preclinical effect of lenvatinib on human thyroid cancer targeting angiogenesis and receptor tyrosine kinase signaling
P3
Hisato Kawakami (Kinki University)
MET amplification as a potential therapeutic target in gastric cancer
P4
Nozomu Fuse (National Cancer Center Hospital East)
Results of phase I study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor
P5
Takayuki Nakagawa (Kanazawa University)
Circumvention of EGFR-TKI resistance associated with BIM polymorphism
P6
Hiromichi Ebi (Kanazawa University)
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
P7
Sho Isoyama (Cancer Chemotherapy Center)
Identification of IGF1R as a responsible factor for acquired resistance to PI3K inhibitors
P8
Yasuhiro Hama (Daiichi Sankyo Co., Ltd.)
Effect of DS-7423, a novel dual PI3K/mTOR inhibitor, on tumor growth and FDG uptake
P9
Daisuke Tatsuda (Institute of Microbial Chemistry, Numazu)
Inhibition of p53-Mdm2 interaction by ellagitannins
P10
Makoto Hasegawa (Nagahama Institute of Bio-Science and Technology
Identification of SAP155 as the target protein of GEX1A (herboxidiene), a pre-mRNA spricing inhibitor.
P11
Akiyoshi Komuro (University of Tokyo)
BMP4 suppresses tumorigenic activity of glioma-initiating cells through loss of stemness properties
P12
Yoshimi Ohashi (Cancer Chemothrapy Center)
A novel golgi disruptor, AMF-26, targets ADP-ribosylation factor 1 (Arf1) with potential for Cancer therapy
17:00
Mixer
December 6
III Cancer Cell Line Panels for Drug Screening
Chairpersons: Michael Kahn and Toshimitsu Uenaka
9:00-9:30
Cyril H. Benes (MGH Cancer Center)
Systematic identification of genomic markers of drug sensitivity in cancer cells
9:30-9:50
Takao Yamori (Pharmaceuticals and Medical Devices Agency, Japan)
JFCR39 cell line panel
9:50-10:00
Discussion
10:00-10:20
Coffee break
Poster Discussion Session
Chairperson: Shiro Akinaga
10:20-10:50
Mentor: Dr. Jaap Verweij
Poster #: P1-P4
10:50-11:20
Mentor: Dr. Mark J. Ratain
Poster #: P5-P8
11:20-11:50
Mentor: Dr. Keith T. Flaherty
Poster #: P9-P12
ILuncheon Seminar
Chairperson: Akihiko Tsuruoka
12:00-12:45
Bruce A. Littlefield (Oncology PCU, Eisai Inc.)
Preclinical discovery, pharmacology, and mechanism of eribulin
IILuncheon Seminar
Chairperson: Toshimitsu Uenaka
12:00-12:45
Felix Garzon (Oncology PCU, Eisai Inc.)
Clinical development of eribulin
To attend the Luncheon Seminars, please receive Luncheon Seminar Ticket at “Luncheon Ticket Desk” . The desk will open from 11:00 on December 5.
13:00-16:00
Poster removal
Special Lecture
Chairperson : Tetsuichiro Muto
13:00-13:40
Jeffrey A. Engelman (MGH Cancer Center)
Resistance to EGFR-TKI in lung cancer
IV Revival of Immune Response or BRAF Inhibition for Cancer Therapy
Chairpersons: Keith T. Flaherty and Ryuzo Ueda
13:40-14:10
Gregory K. Pennock (M.D. Anderson Cancer Center)
Ipilimumab: A novel immunopotentiator
14:10-14:40
Keith T. Flaherty (MGH Cancer Center)
BRAF inhibition as a basis for building combination targeted therapy in melanoma and other cancers
14:40-14:50
Discussion
14:50-15:10
Coffee break
V Targeting FGFR Pathway
Chairpersons: Jeffrey A. Engelman and Saburo Sone
15:10-15:40
Ken Kobayashi (Janssen Pharmaceutical K.K.)
FGFR tyrosine kinase inhibitor
15:40-16:10
Anthony W. Tolcher (START, San Antonio)
Targeting FGR ligands in cancer with the FGF Trap FP 1039
16:10-16:20
Discussion
VI New Drugs under Clinical Trials
Chairpersons: Cyril H. Benes and Shunji Takahashi
16:20-16:50
Glenn Begley (TetraLogic Pharmaceuticals)
IAP binding peptide (Birinapant (TL32711)(SMAC mimetics))
16:50-17:20
Michael Kahn (University of Southern California)
Pharmacologic manipulation of stem cells and cancer stem cells
17:20-17:30
Discussion
Closing remark
17:30-17:40
Jaap Verweij
Closing Remark
